New trial findings suggest that patients with severe bicuspid valve aortic stenosis (AS), who underwent transcatheter aortic valve replacement (TAVR) with the Evolut (Medtronic) bioprosthesis, demonstrates lower rates of all-cause mortality or disabling stroke.